sglt2 inhibitors with glp 1 vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain Diabetic Agents, From Metformin to

This review integrates mechanistic insights with translational advances, outlining how dysregulation of chaperones, autophagy-mitophagy, the ubiquitinproteasome system, and ER stress pathways drive human diseases, while highlighting emerging therapeutic platforms, from pharmacological chaperones and autophagy modulators to targeted protein degradation technologies, CRISPR screens, spatial biology, and AI-guided drug discovery

Wheat proteins: a valuable resource to improve nutritional value of bread

Patients using naltrexone for opioid use disorder face an additional consideration: GLP-1 medications can delay gastric emptying, potentially reducing absorption of oral naltrexone if taken simultaneously

G.VosburgR